Page last updated: 2024-12-07
4,4'-azobis(4-cyanovaleric acid)
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
4,4'-azobis(4-cyanovaleric acid): a free radical initiator [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 92938 |
| CHEMBL ID | 3185815 |
| SCHEMBL ID | 27672 |
| SCHEMBL ID | 786277 |
| MeSH ID | M0241028 |
Synonyms (68)
| Synonym |
|---|
| AC-1880 |
| LS-14095 |
| 4,4'-azo-bis(4-cyanopentanoic acid) |
| 4,4'-azobis-4-cyanovaleric acid |
| 4,4'-azobis(4-cyanovaleric acid), >=98.0% (t) |
| 4-cyano-4-[(e)-(1-cyano-4-hydroxy-1-methyl-4-oxo-butyl)azo]pentanoic acid |
| 4,4'-azobis-(4-cyanovaleric acid) |
| 4,4'-azobis[4-cyanopentanoic acid] |
| nsc114466 |
| nsc-114466 |
| azobis(cyanovaleric acid) |
| valeric acid,4'-azobis[4-cyano- |
| 4,4'-azobis[4-cyanovaleric acid] |
| cis-4,4'-azobis(4-cyanovaleric acid) |
| 2638-94-0 |
| pentanoic acid,4'-azobis[4-cyano- |
| 4,4'-azobis(4-cyanovaleric acid), >=75% |
| valeric acid, 4,4'-azobis(4-cyano- |
| einecs 220-135-0 |
| brn 1729856 |
| kyselina 4,4'-azo-bis-(4-kyanvalerova) [czech] |
| 4,4'-azobis(4-cyanovaleric acid) |
| nsc 114466 |
| 4,4'-azobis(4-cyanopentanoic acid) |
| pentanoic acid, 4,4'-azobis(4-cyano- |
| 4,4'-azobis(4-cyanovaleric) acid |
| 4,4'-azo-bis(4-cyanovaleric acid) |
| cas-2638-94-0 |
| tox21_302513 |
| dtxsid3044629 , |
| dtxcid1024629 |
| NCGC00256797-01 |
| 4,4'-diazene-1,2-diylbis(4-cyanopentanoic acid) |
| AKOS024348893 |
| acva |
| abcva |
| 4,4'-(diazene-1,2-diyl)bis(4-cyanopentanoic acid) (contains up to 18% water) |
| kyselina 4,4'-azo-bis-(4-kyanvalerova) |
| 4-04-00-03382 (beilstein handbook reference) |
| pentanoic acid, 4,4'-(1,2-diazenediyl)bis(4-cyano- |
| AKOS015853607 |
| 4,4-azobis(4-cyanovaleric acid) |
| 4-[2-(3-carboxy-1-cyano-1-methylpropyl)diazen-1-yl]-4-cyano-4-methylbutanoic acid |
| 1041193-98-9 |
| SCHEMBL27672 |
| VFXXTYGQYWRHJP-UHFFFAOYSA-N |
| v-501 |
| (e)-4,4'-(diazene-1,2-diyl)bis(4-cyanopentanoic acid) |
| VFXXTYGQYWRHJP-FOCLMDBBSA-N |
| SCHEMBL786277 |
| c12h16n4o4 |
| W-107175 |
| 4,4'-(diazene-1,2-diyl)bis(4-cyanopentanoic acid) |
| CHEMBL3185815 |
| benzene, 1-bromo-4-(1-propyn-1-yl)- |
| mfcd00002799 |
| pentanoic acid, 4,4'-azobis[4-cyano- |
| FT-0700071 |
| 4,4'-(diazene-1,2-diyl)bis(4-cyanopentanoic acid) (contains ca. 20% water) |
| Q4637047 |
| FS-4446 |
| pentanoic acid, 4,4'-(1,2-diazenediyl)bis[4-cyano- |
| 4-[(4-carboxy-2-cyanobutan-2-yl)diazenyl]-4-cyanopentanoic acid |
| CS-W012275 |
| DTXSID00859752 |
| 4,4'-(1e)-1,2-diazenediylbis[4-cyanopentanoic acid] |
| EN300-1705965 |
| 4-[(e)-2-(3-carboxy-1-cyano-1-methylpropyl)diazen-1-yl]-4-cyano-4-methylbutanoic acid |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (3)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 48.5577 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 48.5577 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 76.9588 | 0.0003 | 23.4451 | 159.6830 | AID743066 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Research
Studies (10)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (30.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 2 (20.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 40.57
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (40.57) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 11 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||